Navigation Links
A Biologic Drug Superior to Spiriva in Reducing COPD-Related Exacerbations Would Earn a Higher Patient Share in Europe Than in the U.S.
Date:1/12/2009

Spiriva Will Remain the Gold Standard Treatment Through 2017, According to a New Report from Decision Resources.

WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a biologic drug that is superior to Boehringer Ingelheim/Pfizer's Spiriva in reducing yearly COPD-related exacerbations would earn a higher patient share in Europe (30 percent) than in the U.S. (15 percent) according to surveyed European and U.S. pulmonologists. COPD-related exacerbations are episodic events often requiring hospitalization.

"A biological drug that provides fewer yearly COPD-related exacerbations compared to current therapies holds much commercial promise," said Regina Jammen, M.S., analyst at Decision Resources. "Enthusiasm from U.S. and European pulmonologists for a biologic drug with the potential to dramatically reduce yearly exacerbation rates likely reflects physicians' recognition of not only the long-term therapeutic benefits of such a drug, but also its economic benefits."

The new report entitled Chronic Obstructive Pulmonary Disease: Blockbuster Potential Exists for Biologic Drugs That Dramatically Reduce Exacerbation Rates finds that Spiriva will remain Decision Resources' clinical gold standard treatment for COPD over the next eight years even though emerging drugs such as Forest/Almirall's aclidinium, Novartis's indacaterol, Boehringer Ingelheim's BI-1744/tiotropium and Nycomed/Mitsubishi Tanabe's roflumilast will offer therapeutic benefits to COPD patients.

About the Report

Chronic Obstructive Pulmonary Disease: Blockbuster Potential Exists for Biologic Drugs That Dramatically Reduce Exacerbation Rates is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need,
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Biologic treatment for rheumatoid arthritis and the risk of cancer
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Neurobiological Technologies Reports Going Concern Qualification
4. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
5. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
6. Study questions assumptions about human sensitivity to biological motion
7. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
8. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
9. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
10. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
11. CalbaTech Reports That LifeStems Biologics License Has Been Renewed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 Orem, UT—Dymicron, Inc., (dymicron.com) ... using their unique Triadyme-C cervical total disc replacement device. ... William D. Smith at the American Institute of Minimally ... are responding well to the implantation of the Dymicron ... Spine Center and Chief of Neurosurgery for the University ...
(Date:5/28/2015)... Omaha, NE (PRWEB) May 28, 2015 ... healthcare staffing, including nurse practitioner jobs, has announced that ... Association of Nurse Practitioners’ 2015 National Conference to be ... , AANP offers educational programming, networking opportunities, and ... Aureus Medical’s Advanced Practice division will be ...
(Date:5/28/2015)... 2015 Peggy J. Lynam, PT, DPT, NCS ... American Physical Therapy Association House of Delegates for the New ... Delegate Assembly. This will be her second term. ... coordinator and principle spokesperson for the Chapter delegation and presides ... or Delegate Assembly may direct the Chief Delegate to present ...
(Date:5/27/2015)... Gravity and volume loss in the skin have ... Holly CaSaroll, is excited to introduce a custom menu ... face, without surgical intervention, and without downtime. , “We ... approved procedure that can lift skin using focused ultrasound, ... new more lifting formula than its predecessor Radiesse, to ...
(Date:5/27/2015)... Thermage was the first to come out with ... 2007 coinciding with the release of NXT or CPT, the ... Aesthetics was the first practice in New York to debut ... results that had never been achieved before non-surgically. Even ... considered by many as the leading skin tightening device. ...
Breaking Medicine News(10 mins):Health News:Dymicron, Inc., Announces the First Human Implantation of their Triadyme-CTM Cervical Total Disc Replacement Device in Cyprus 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the American Association of Nurse Practitioners’ 2015 National Conference 2Health News:Skin Expert Holly CaSaroll Announces New Cutting Edge Results with RadiessePlus Filler Available at Detroit Skin and Wellness Clinic 2Health News:Non-Surgical Fat Reduction and Skin Tightening Procedures, Thermage and Exilis, Increase 200% at Precision Aesthetics in New York, April 2015 2
... hospital ranked as one of Americas Best by U.S. News ... days than those admitted to a non-ranked hospital , according ... of Internal Medicine, one of the JAMA/Archives journals. ... mortality measures that are publicly reported by the Centers for ...
... eating uncooked fish dishes like koi-pla puts people in ... cause a type of liver cancer called cholangiocarcinoma ... weeks PLoS Medicine. ,Banchob Sripa (Khon Kaen ... food-borne trematode Opisthorchis viverrini (the SE Asian liver fluke) ...
... research, published in the July issue of the journal ... method for enhancing the potency and effectiveness of ... a variety of human cancers. , A ... human cancer cells to a promising treatment currently being ...
... According to a study published in the July 10, ... American Academy of Neurology , People with early Parkinsons ... of hallucinations, sleepiness, and swelling. ,By identifying ... for early intervention and possibly reduce disability, said study ...
... fashion designer Giorgio Armani's group said Wednesday it will open ... of both hot springs and high fashion. ... Ginza, one of Tokyo's ritziest districts, as part of its ... market. ,The 6,000 square-meter (65,000 square-foot) complex opening ...
... of British scientists claims they can soon release the worlds ... so, the NHS Trust of UK will stand to save billions ... most common neurological diseases in the western world, costs the NHS ... scientists, they have identified a series of proteins, which are most ...
Cached Medicine News:Health News:Americas Best Hospital Reduced Heart Attack Rates 2Health News:Americas Best Hospital Reduced Heart Attack Rates 3Health News:New Cancer Therapy in Clinical Trial 2Health News:Early Parkinsons Show Hallucination,sleepiness 2Health News:Simple Blood Test May Predict Alzheimers Disease 2
(Date:5/27/2015)... , May 27, 2015 PharmaPoint: Type 1 Diabetes ... Summary Type 1 diabetes (T1D) is an autoimmune disease ... means that the body can no longer produce insulin. Over ... as at present, no other treatment can be offered to ... of insulin analogs with different times of action - long-acting ...
(Date:5/27/2015)... 27, 2015  Precision Advisors ( www.precisionadvisors.com ), a ... 2015 Digital Trends Study of 145 managed care executives. ... the concepts of big data and predictive analytics, but ... The Health Information Technology for Economic and Clinical ... make use of electronic medical records (EMRs) by 2014. ...
(Date:5/27/2015)... -- LumiThera Inc., a developmental stage medical device company ... disorders and disease, announced today that they were ... Life Sciences Discovery Fund (LSDF) commercialization grant. LumiThera was ... grants worth $500,000 to provide for commercialization activities ... macular degeneration (AMD). LSDF executive ...
Breaking Medicine Technology:PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 2Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 3LumiThera Receives LSDF Commercialization Grant Award 2
... TUSTIN, Calif., Dec. 5, 2011  Radient Pharmaceuticals Corporation ... In Vitro Diagnostic (IVD) cancer test, ... to the 2012 Gastrointestinal Cancers Symposium (ASCO Conference) ... submitted. The meeting will be held on January ...
... ANGELES, December 2, 2011  WestPark Capital, Inc. announced the ... Amex: ISR). A total of 2,817,988 shares of common stock ... common stock were sold, generating gross proceeds of $2,592,549 ... to fund new applications for IsoRay,s Cesium-131 technology to ...
Cached Medicine Technology:Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation 2Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation 3WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering 2
... Ultra thin collagen coated highly ... ultra thin wall construction offers ... The Hemacarotid UltraThin Patch provides ... conformability, and healing, without suture ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
... EVS is engineered to close arteriotomies ... ergonomic stapler with a simple trigger ... A deliver sheath gently locks ... control of the site before, during, ...
Medicine Products: